Special
Directors Dealings
Director dealings are proprietary transactions by executives, which are reportable under Art. 19 MAR. The publication of these transactions is an important contribution to the prevention of insider dealing and market manipulation. In addition, knowledge of such transactions is of great importance to the market, as these transactions provide indications of management's assessment of the company's future business prospects. The information presented here relates to companies that are under the supervision of BaFin.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael 
. The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
BRAIN Biotech AG: A reportable insider transaction was published on 20th April 2023. The reporting obligation was triggered by a person related to Supervisory Board.
Transaction reporting date: 20th April 2023,
The Insider Transaction was made by Majerus, Dr. Michael . The transaction toke place on 18th April 2023. The order was executed at the trading place XETRA. . The aggregated volume was 142.290,60 EUR, based on an average price of 5,69 EUR. The nature of the Investment was Buy.
| Type | Total | Last | Made by | Go to |
|---|---|---|---|---|
| Equity Story | 93 | 12th December 2024 | EQS Group AG | EQS |
| Corporate Research | 0 | - | - | Corporate Research |
| Short Seller (DE) | 0 | - | - | SSR (DE) |
| Short Seller (UK) | 0 | - | - | SSR (UK) |
Disclaimer:
The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster.
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.
If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.